Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2010

View Archived Issues

PTC-299/aromatase inhibitor combinations deemed feasible in breast cancer trial

Debio-0719 suppresses metastasis in mouse models of breast cancer

PP-9706642 shows promise as a prophylactic/therapeutic agent for HSV-2 infection

University of Connecticut claims new cannabinoid CB1 receptor antagonists

Apogee Biotechnology discovers new sphingosine kinase inhibitors

Taiho Pharma claims new H-PGDS inhibitors

French scientists present new inhibitors of CDK1, CDK5 activator 1 and/or GSK-3

Targacept reports clinical data on AZD-1446 in ADHD and AD

StemCells advances phase I trial of HuCNS-SC cells in Pelizaeus-Merzbacher disease

MD Anderson Cancer Center investigates antitumor potential of CG-100649

Adeona Pharma advances CopperProof-2 trial of Zinthionein

Tasocitinib meets primary endpoint in phase II psoriasis trial

VentiRx reports clinical data on VTX-1463 in allergic rhinitis

Neuronex is launched to develop drugs for CNS diseases

Onyx Pharma delays NDA submission for carfilzomib

NephRx provides update on new peptides, NX-001 and NX-002

Biotron begins phase II trial of BIT-225 in hepatitis C

Amylin Pharma to use Affibody's Albumod platform under new license agreement

New inhibitors of beta-secretase 1 disclosed by Medivir

Novel tachykinin NK3 receptor antagonists claimed by Roche

AGI-101 improves postsurgery survival in high-risk melanoma

Abbott to withdraw obesity drug Meridia from U.S. market

Bayer's contraceptive Qlaira approved in E.U. to treat heavy menstrual bleeding

Merck KGaA to appeal CHMP's opinion on cladribine tablets in MS

Recordati and Almirall launch silodosin for treatment of BPH symptoms in Spain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...